Tandem Diabetes Care's stock experienced a significant pre-market plunge of 7.64% following the company's announcement of a proposed private placement of convertible senior notes.

The insulin pump maker revealed plans to offer $200 million in convertible notes due 2032, with an option for initial purchasers to buy up to an additional $30 million. This capital raising move typically creates downward pressure on stock prices due to investor concerns about potential dilution when the notes are converted into shares and the increased debt burden on the company's balance sheet.

The company plans to use the net proceeds for general corporate purposes, including potential acquisitions, strategic investments, working capital, and operating expenses, while also allocating a portion to fund capped call transactions designed to help offset potential dilution.